argenx SE (LON: 0QW0)

London flag London · Delayed Price · Currency is GBP · Price in EUR
352.20
-4.84 (-1.36%)
Jul 25, 2022, 8:02 AM BST
-15.15%
Market Cap 30.24B
Revenue (ttm) 1.42B
Net Income (ttm) -30.06M
Shares Out n/a
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2
Open 352.20
Previous Close 357.04
Day's Range 352.20 - 352.20
52-Week Range 314.70 - 494.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Feb 27, 2025

About argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 1,148
Stock Exchange London Stock Exchange
Ticker Symbol 0QW0
Full Company Profile

Financial Performance

In 2023, argenx SE's revenue was $1.27 billion, an increase of 187.66% compared to the previous year's $441.01 million. Losses were -$295.05 million, -58.42% less than in 2022.

Financial numbers in USD Financial Statements

News

There is no news available yet.